Ipamorelin: What the Clinical Record Shows
Ipamorelin is a growth hormone secretagogue that reached Phase 2 and stopped there. What the 1998 pharmacology found, and what the marketing leaves out.
Start here
Plain English
Ipamorelin is a research growth hormone secretagogue with published pharmacology going back to 1998 and a clinical programme that reached Phase 2 without becoming an approved drug. It is not a legal over-the-counter fat-loss peptide.
- Not FDA-approved for any indication we treat as settled medicine.
- Early clinical work does not equal proven consumer therapy.
- Sold in research channels; sport rules may prohibit related agents.
Ipamorelin is sold online with the confidence of a finished medicine. It is not one.
It is a research-only growth hormone secretagogue with a real pharmacology paper, a clinical development history that stopped for lack of efficacy, and no approval anywhere.
What it is
Ipamorelin is a pentapeptide: Aib-His-D-2-Nal-D-Phe-Lys-NH2. It was developed at Novo Nordisk as NNC 26-0161 and later investigated by Helsinn. Parts of that corporate history reach us through secondary sources rather than a single neat primary package insert - because there is no approved label.
The 1998 finding everyone quotes
Raun and colleagues characterised ipamorelin as a selective growth hormone secretagogue acting via the GHRP receptor pathway (later understood in the ghrelin receptor family). In rat pituitary cells, rats, and conscious swine, it released GH with potency in the range of GHRP-6, without the same ACTH/cortisol rise those authors observed with some other GHRPs. Raun 1998 - Raun K, Hansen BS, Johansen NL et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. (opens PubMed in a new tab)
That is animal and in vitro pharmacology. It is interesting. It is not a human lifestyle indication.
Human development: it failed the job it was given
Ipamorelin reached Phase 2 for postoperative ileus and development was discontinued for insufficient efficacy. That fact is the opposite of the influencer version of the molecule.
There is human pharmacokinetic information discussed in secondary literature (including a terminal half-life on the order of a couple of hours from a Phase 1 context). We treat secondary half-life figures as likely, not independently verified, when the primary paper is not in hand.
Small or uncontrolled human studies. Too little to settle the question either way. Strong animal/in vitro GH-release pharmacology; human development discontinued for insufficient efficacy in postoperative ileus; no approved indication.
Legal and sport status
US legal status - Research use only · not for human use
Sold for laboratory research use only. Not approved by the FDA for human use, and cannot be lawfully marketed as a supplement or a medicine. Products sold this way are not made to pharmaceutical quality standards, and their contents are not verified by anyone.
AU legal status - Not on the ARTG
Schedule 4 of the Poisons Standard, named directly, and Appendix D, clause 5 - prescription only, and possession without authority is illegal. Appendix D covers growth hormone secretagogues as a class as well, so a renamed one is caught whether or not it is listed by name. Nothing containing it is on the ARTG.
Regulators reach their own conclusions on their own timelines. Where these two disagree, the difference is the point - not an error.
- Not FDA-approved for any use.
- Sold by research-chemical vendors as not for human use.
- FDA compounding policy materials have listed ipamorelin acetate among substances associated with potential significant safety risks in the category 2 bulk-substance context.
- WADA 2026 lists growth hormone secretagogues such as ipamorelin under S2.2.4, prohibited at all times in sport.
What marketing leaves out
| Claim you will see | What we can actually say |
|---|---|
| “Selective GH release without cortisol” | Shown in animal/in vitro work from 1998; not established as a clinical benefit package in humans. |
| “Safe peptide for recovery” | Never approved; Phase 2 stopped for efficacy, not because long-term consumer safety was proven. |
| “Research pure = fine to take” | Research-only labelling is a sales category, not a safety certificate. |
Related reading
References
Bibliographic detail is fetched from PubMed, not written by us - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than our judgement.
- 1.Raun K, Hansen BS, Johansen NL et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61.StudyPMID 9849822
- 2.Ipamorelin - secondary reference for development history (Novo Nordisk NNC 26-0161, Helsinn), Phase 2 postoperative ileus discontinuation, and half-life figures reported secondarily.- Wikipediaother
- 3.FDA - Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (category 2 table lists ipamorelin acetate, 503B context).- US Food and Drug Administrationregulatory
- 4.WADA 2026 Prohibited List - growth hormone secretagogues under S2.2.4 (national anti-doping agency mirror, PDF).- World Anti-Doping Agency (mirrored by the Jamaica Anti-Doping Commission)regulatory
- 5.Therapeutic Goods (Poisons Standard - June 2026) Instrument 2026, the current Poisons Standard (SUSMP). Ipamorelin is a Schedule 4 (prescription only) entry, and Appendix D, clause 5 - which also covers growth hormone secretagogues as a class.- Federal Register of Legislation, Australian Governmentstatute
- 6.TGA - Unapproved therapeutic goods. Goods not on the ARTG have not been assessed by the TGA for safety, quality or effectiveness, and reach patients only through defined pathways such as the Special Access Scheme.- Therapeutic Goods Administration, Australian Governmentregulatory